Literature DB >> 12830466

Changes in viremia and circulating interferon-alpha during hemodialysis in hepatitis C virus-positive patients: only coincidental phenomena?

Salvatore Badalamenti1, Anna Catania, Giovanna Lunghi, Giovanni Covini, Elena Bredi, Diego Brancaccio, Maurizio Salvadori, Giovanna Como, Claudio Ponticelli, Giorgio Graziani.   

Abstract

BACKGROUND: It has been hypothesized that hemodialysis (HD) treatment per se can preserve patients from an aggressive course of hepatitis C virus (HCV) infection by reduction of viral load. The aim of the present study in HCV-positive (HCV+) HD patients is to determine whether HD induces the production of interferon-alpha (IFN-alpha) and if such production can contribute to viremia reduction.
METHODS: To address this issue, HCV RNA and IFN-alpha levels were determined in 11 HCV+ patients immediately before and at the end of a 4-hour dialysis session using cellulosic membranes and 24 and 48 hours later, ie, immediately before the subsequent dialysis session using the same membrane and at the end of the dialysis session. The same protocol was repeated 1 week later using a high-biocompatibility synthetic membrane.
RESULTS: HCV titer decreased in all patients after dialysis (range, 3% to 95%; P = 0.001) and thereafter progressively increased and returned to basal levels within 48 hours, with a new reduction during the next dialysis treatment. There was no significant difference in the magnitude of changes in HCV titers in tests performed using cellulosic or synthetic membranes. Plasma IFN-alpha levels increased markedly after dialysis using both cellulosic (in 9 of 11 cases) and synthetic membranes (in 10 of 11 cases; P < 0.01) and returned to basal levels within 48 hours; thereafter, IFN-alpha levels increased again during the next dialysis session. In some patients, plasma IFN-alpha levels after HD were approximately 50% of the level observed after therapeutic administration of 6 million units of IFN-alpha to 4 HD patients with chronic hepatitis.
CONCLUSION: Although without a proven direct cause-effect relationship between HCV level reduction and induction of IFN-alpha after dialysis, our observation suggests an additional new mechanism for the unusually mild course of HCV infection in HD patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12830466     DOI: 10.1016/s0272-6386(03)00417-7

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  12 in total

Review 1.  Hepatitis C in hemodialysis patients.

Authors:  Smaragdi Marinaki; John N Boletis; Stratigoula Sakellariou; Ioanna K Delladetsima
Journal:  World J Hepatol       Date:  2015-03-27

2.  Hepatitis C virus and its renal manifestations: a review and update.

Authors:  Nyan Latt; Nada Alachkar; Ahmet Gurakar
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-07

Review 3.  Management of hepatitis C in patients with chronic kidney disease.

Authors:  Roberto J Carvalho-Filho; Ana Cristina C A Feldner; Antonio Eduardo B Silva; Maria Lucia G Ferraz
Journal:  World J Gastroenterol       Date:  2015-01-14       Impact factor: 5.742

4.  Relevance of low viral load in haemodialysed patients with chronic hepatitis C virus infection.

Authors:  Jan Sperl; Sona Frankova; Renata Senkerikova; Magdalena Neroldova; Vaclav Hejda; Miroslava Volfova; Dusan Merta; Ondrej Viklicky; Julius Spicak; Milan Jirsa
Journal:  World J Gastroenterol       Date:  2015-05-14       Impact factor: 5.742

5.  Hepatitis B viral infection in maintenance hemodialysis patients: a three year follow-up.

Authors:  Ya-Li Cao; Shi-Xiang Wang; Zuo-Min Zhu
Journal:  World J Gastroenterol       Date:  2007-12-07       Impact factor: 5.742

6.  Efficacy and tolerability of low-dose interferon-α in hemodialysis patients with chronic hepatitis C virus infection.

Authors:  Kai-Li Wang; Han-Qian Xing; Hong Zhao; Jun-Wei Liu; Deng-Lian Gao; Xue-Hua Zhang; Hong-Yu Yao; Li Yan; Jun Zhao
Journal:  World J Gastroenterol       Date:  2014-04-14       Impact factor: 5.742

7.  Hepatitis C is less aggressive in hemodialysis patients than in nonuremic patients.

Authors:  Jose Eduardo Trevizoli; Raissa de Paula Menezes; Lara Franciele Ribeiro Velasco; Regina Amorim; Mauro Birche de Carvalho; Liliana Sampaio Mendes; Columbano Junqueira Neto; José Roberto de Deus Macedo; Francisco de Assis; Rocha Neves
Journal:  Clin J Am Soc Nephrol       Date:  2008-07-23       Impact factor: 8.237

Review 8.  Hepatocyte growth factor (HGF) and hemodialysis: physiopathology and clinical implications.

Authors:  Carmelo Libetta; Pasquale Esposito; Claudia Martinelli; Fabrizio Grosjean; Marilena Gregorini; Teresa Rampino; Antonio Dal Canton
Journal:  Clin Exp Nephrol       Date:  2015-12-16       Impact factor: 2.801

9.  The reduction of serum aminotransferase levels is proportional to the decline of the glomerular filtration rate in patients with chronic kidney disease.

Authors:  Luís Henrique Bezerra Cavalcanti Sette; Edmundo Pessoa de Almeida Lopes
Journal:  Clinics (Sao Paulo)       Date:  2015-05-01       Impact factor: 2.365

10.  Serum alanine aminotransferase levels, hematocrit rate and body weight correlations before and after hemodialysis session.

Authors:  Edmundo Pessoa Lopes; Luis Henrique B C Sette; Jorge Bezerra C Sette; Carlos F Luna; Amaro M Andrade; Maviael Moraes; Paulo C A Sette; Roberto Menezes; Rui L Cavalcanti; Sergio C Conceição
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.